← Back
OKYO Pharma
OKYO · listed on Nasdaq · worth $82.39 million
$1.46
−0.68% on Nov 2
Seven insider buys in the last year, $136K in all. None in the last two weeks.
Green dot = an insider boughtA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
27.9M shares
53% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, six insiders bought OKYO Pharma stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Gabriele M. Cerrone
Bought $35K on Jul 20 — 25,000 shares at $1.40, held through a trust or family, 0.2% of what they now own.
No earlier purchases to measure
CHIEF MEDICAL OFFICER
Flavio Mantelli
Bought $28K on Jul 21 — 20,000 shares at $1.40, 100% of what they now own.
No earlier purchases to measure
CHIEF EXECUTIVE OFFICER
Robert John Dempsey
Bought $23.1K on Jul 22 — 15,000 shares at $1.54, 100% of what they now own.
No earlier purchases to measure
All reports
Every insider trade and SEC report we hold for OKYO Pharma.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 7BoughtRobert John DempseyAug 7 · Traded Jul 22 · CHIEF EXECUTIVE OFFICER+100%15,000 @ $1.54$23.1K
Aug 7BoughtGabriele M. CerroneAug 7 · Traded Jul 21 · 10% owner+0.2%via a trust or family22,500 @ $1.45$32.6K
Aug 7BoughtGabriele M. CerroneAug 7 · Traded Jul 20 · 10% owner+0.2%via a trust or family25,000 @ $1.40$35K
2 more with Pro →Analysts, earnings and news
Analysts' price target
$8.33 average
3 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.